A healthcare research firm built its edge by reaching people conventional panels struggled to find. Its next challenge is making years of accumulated research easier to use.
For years, a pharma study ended with a deck and a folder. ZoomRx is betting that its 60,000-plus-member panel, 700 million benchmark data points and new AI products can turn those forgotten files into a living commercial memory.